A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 11 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 08 Mar 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Apr 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.